The Neuropathy Action Foundation and the GBS/CIDP Foundation International have launched a joint nationwide campaign to raise awareness of multifocal motor neuropathy.
Novovax Inc.’s quadrivalent seasonal influenza virus-like particle (VLP) vaccine demonstrated the company’s PhaseII clinical trial’s primary endpoint of safety and immunogenicity of three ascending dose levels.
In a prospective, multicenter, single-arm, open-label PhaseIII study, 61 percent of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) responded to induction and maintenance therapy with a 10% liquid human intravenous immunoglobulin (IVIG) (Privigen, CSL Behring).
The Centers for Disease Control and Prevention has updated its recommendations for the use of VariZIG.
A recent study conducted to evaluate barriers to pregnant women’s uptake of the influenza vaccine found that the decline in vaccination among this population was due to lower levels of knowledge and unfavorable attitudes regarding the vaccine’s safety and efficacy.
The Department of Health and Human Services and Young Invincibles launched a video contest to inform young people about health insurance coverage under the Affordable Care Act.
A study by researchers at RTI International and the U.S. Centers for Disease Control and Prevention showed that two-dimensional barcodes on vaccine product labels would enhance the safety of the U.S. immunization system and save more than $300 million by 2023.
The U.S. Food and Drug Administration has approved a 10 g (50mL) vial size for Hizentra, immune globulin subcutaneous (human).
The U.S. Food and Drug Administration has approved two new quadrivalent influenza vaccines (IIV4s).
The U.S. Food and Drug Administration has launched the Secure Supply Chain Pilot Program (SSCPP) to enable qualified firms to expedite the importation of active pharmaceutical ingredients and finished drugs into the United States.
A total of 4,659 adults aged 18 years or older were randomized to receive a single dose of inactivated quadrivalent influenza vaccine (IIV4) from one of three production lots or an inactivated trivalent influenza vaccine (IIV3) containing either a B/Victoria or B/Yamagata strain.
The National Governors Association reports states are pursuing policies intended to reduce healthcare costs, enhance outcomes and improve access to care for children and pregnant women.
